Rafferty Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Rafferty Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,940	Closed	-$153K	–	1121
2023 Q1	$153K	Buy	+10,940	New	+$157K	﹤0.01%	1111
2022 Q2	–	Sell	-6,320	Closed	-$223K	–	1192
2022 Q1	$223K	Buy	+6,320	New	+$212K	﹤0.01%	1133

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Rafferty Asset Management's MRVI Position: Q2 2023 in Review

Rafferty Asset Management sold out of Maravai LifeSciences (MRVI) in Q2 2023, closing a stake of 10,940 shares — an estimated $153K sold.

Rafferty Asset Management first reported a position in MRVI in Q1 2022 and held it in 2 quarters. The position peaked at $223K in Q1 2022. 221 funds tracked by Wall St. Rank hold MRVI as of Q2 2023.

Rafferty Asset Management reported no remaining Maravai LifeSciences position as of Q2 2023 after selling out during the quarter.
Rafferty Asset Management sold 10,940 Maravai LifeSciences shares in Q2 2023, an estimated $153K.
Rafferty Asset Management first reported a position in Maravai LifeSciences in Q1 2022 and held it in 2 quarters.
Rafferty Asset Management's Maravai LifeSciences position peaked at $223K in Q1 2022.
221 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2023.

Based on Rafferty Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.